Pharmaceutical development in Sweden – our research and development
Auxesis Pharma conducts pharmaceutical development in Sweden with a focus on topical, localized analgesic treatment based on a stable liquid form of acetylsalicylic acid.
The company develops topical treatments for both people and animals, designed for everyday use as well as clinical care.
In parallel, projects are underway to develop prescription medicines for more complex skin-related pain conditions.
Swedish research with the skin as the starting point
Auxesis Pharma conducts pharmaceutical development in Sweden with a focus on localized topical analgesic treatment. Our research is based on a stable liquid form of acetylsalicylic acid, enabling pain to be treated where it occurs – directly on the skin.
We develop medicines for both people and animals, with the goal of providing safe topical treatments suitable for everyday life as well as healthcare settings.
We also have ongoing projects focused on developing new prescription medicines for more severe topical skin pain conditions.
All research and development is conducted in Sweden, in close collaboration between chemists, pharmacists, product developers and clinical advisors.
Our focus is on medicines that act locally on the skin for:
- insect bites and stings
- irritation and inflammation
- minor burns and sunburn
- skin pain in both people and animals
Our technology for localized analgesic treatment on the skin
Acetylsalicylic acid is one of the world’s most well-known substances for pain and inflammation. Despite this, a stable liquid formulation for topical skin use has long been missing.
Auxesis has developed a technology that keeps acetylsalicylic acid stable in liquid form over time. This enables topical, ASA-based analgesic treatment to be used in a controlled and effective manner.
The treatment acts where the pain occurs, without unnecessary systemic exposure.
How localized COX-2 inhibition works in the skin
What is COX-2?
COX-2 (cyclooxygenase-2) is an enzyme that plays a central role in inflammatory processes. It is produced in response to injury or inflammation.
- Pain: Amplifies pain signaling
- Inflammation: Contributes to the inflammatory response
Topical COX-2 inhibition
Our products block COX-2 locally, providing:
- Targeted effect only where the skin is affected
- Eliminates pain from insect bites, stings and irritation
- Lower risk of systemic side effects
From concept to clinical studies
Our journey began with fundamental research into how acetylsalicylic acid can be stabilized in liquid form and work topically. Today, we have:
- developed a stable formulation with at least two years of shelf life
- developed topical formulations for both human and veterinary medicine
- prepared documentation for upcoming clinical studies
After nearly ten years of research, Auxesis Pharma is now entering the clinical phase. In 2026, the first clinical studies of ASA.P will begin – a topical medicine with localized analgesic action.
Reaching the clinical phase means the formulation is tested in humans under a regulatory-approved protocol. This marks a clear shift from a research company to a clinical development company.
The next step is to evaluate efficacy and safety in controlled studies, initially targeting short-term skin pain and irritation.
Focus of our clinical studies
The first studies are conducted in healthy volunteers and verify three key aspects:
That the formulation penetrates the outermost layer of skin (epidermis)
That it delivers the intended localized analgesic effect
That it does not cause systemic side effects
People (ASA.P)
Studies of topical, ASA-based analgesic treatment for skin pain, such as insect bites and irritation.
Learn more about ASA.PAnimals (CoxyPet)
Studies of topical treatment for localized skin pain and inflammation, in collaboration with veterinarians.
Learn more about CoxyPetCollaborations in pharmaceutical development
Auxesis collaborates with researchers, clinics and manufacturing partners in Sweden. This includes, for example:
- formulation experts in dermal medicines
- dermatology specialists in topical treatment methods
- veterinary development through CoxyPet
Together, we are building a platform for topical medicines with global scalability.
AFRY
AFRY supports Auxesis in planning and building a sustainable production model, including support in medical R&D, work with the Swedish Medical Products Agency and the establishment of the manufacturing unit in Östersund.
Visit AFRY
IQVIA and Swedish Pharmaceutical Statistics
IQVIA and Swedish Pharmaceutical Statistics provide comprehensive analyses of the pharmaceutical sector in Sweden and globally. Through rigorous analytics and tailored consulting, Auxesis gains valuable insights for decision-making.
Visit IQVIA
Zelmic
Zelmic develops topical and transdermal pharmaceutical formulations and supports Auxesis’ formulation work. They are an experienced, privately owned CRO and CDMO.
Visit Zelmic
RegSmart Life Science
RegSmart Life Science AB supports Auxesis with regulatory matters related to the commercialization of ASA.P®. They navigate a complex and evolving regulatory landscape.
Visit RegSmartProduct development
Our product development is carried out in close collaboration between chemists, pharmacists and clinical advisors. We work step by step – from concept and formulation, through stability testing, to a finished product.
Today, we have developed a stable formulation with at least two years of shelf life and topical formulations for both human and veterinary medicine.
See our products
Our unique formulation is protected through strategic patent applications.
Auxesis Pharma protects its technology through patents. Our stable liquid acetylsalicylic acid formulation for topical use is a key part of our intellectual property protection. The patent portfolio is continuously developed as new innovations emerge.
The names ASA.P, CoxyPet and AUXESIS ASA.P are protected through global trademark portfolios, including the US, EU, China, India, Japan and the United Arab Emirates among the 50+ territories where protection is in place.
Innovation is at the core of everything we do.
By combining established science with new technology, we create medicines that address real needs – from everyday issues like mosquito bites to more complex skin conditions.
The goal is clear: to make topical ASA a natural first-choice option for skin pain.
More about upcoming productsTransparency and safety
Safety is a central part of our development. We follow applicable ethical guidelines and document every step of the process.
Our goal is to develop topical medicines for skin pain that are both effective and safe to use – for patients, pet owners and healthcare professionals.